CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 20 enrolled
Drug / intervention
SVF injectionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03060551
NCT03060551Early Ph 1Completed
CompareCT.gov

Safety, Tolerability and Potential Efficacy of Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients

Suk-Ho Moon·interventional·Posted Feb 23, 2017·Updated Oct 8, 2020

In Brief

A Early Phase 1 clinical trial evaluating SVF injection for Systemic Sclerosis. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study outlines the safety of the autologous SVF cells injection in the hands of patients with SSc. Preliminary assessments at 6 months will suggest potential efficacy needing confirmation in a randomised placebo-controlled trial on a larger population

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesSouth Korea
Collaborators--

Timeline

Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 23, 2017
Enrollment StartJul 1, 2018
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.4 years ago

Interventions

SVF injectionprocedure

SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis